Table 1.
Clinical and phenotype characteristics of multiple sclerosis patients.
| AGE (YEARS) | MS PHENOTYPE | MS EVOLUTION TIME (YEARS) | EDSS | NO. OF PREVIOUS TREATMENTS | PREVIOUS TREATMENT | COMORBIDITIES | MS TREATMENT | TREATMENT TIME | LAST INFUSION | CD19+ T lymphocytes | Previous lymphopenia | COVID-19 DATE | SARS-CoV-2 RT-PCR | Chest x-rays | COVID-19 Lymphopenia | OTHERS | HOSPITALIZATION | COVID-19 SEVERITY | COVID-19 TREATMENT | IMMUNIZATION | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATIENT 1 | 60 | PMS | 10 | 8 | 2 | Natalizumab | no | Rituximab | 3 years | July 2019 | Absent, December 2019 | no | 17 March 2020 | POSITIVE | Unilateral pneumonia | 0.60 × 103/mm3 | Fibrinogen: 489, d-DIMER: 0.54, LDH: 255, CRP: 9.3, | YES | SEVERE | Hydroxychloroquine 200 mg/12 h 10 days | NOT DETERMINED |
| PATIENT 2 | 49 | RRMS | 6 | 3 | 1 | Glatiramer Acetate | Smoker | Ocrelizumab | 3 years | January 2019 | Absent, January 2020 | no | 11 March 2020 | POSITIVE | Normal | 0.51 × 103/mm3 | YES | MODERATE | lopinavir/ritonavir 200/50 mg 2 tablets/12 h | IgM- IgG+ | |
| PATIENT 3 | 45 | RRMS | 5 | 2 | 1 | Teriflunomide | no | Ocrelizumab | 3 years | January 2020 | Absent, January 2020 | no | 3 April 2020 | POSITIVE | Bilateral pneumonia | NO | CRP 0.83 mg/dl | YES | SEVERE | Hydroxychloroquine 200 mg/12 h 10 days, lopinavir/ritonavir 200/50 mg 2 tablets/12 horas, Azithromycin 250 mg/24 h 4 days | IgG+ IgM+ |
| PATIENT 4 | 25 | RRMS | 8 | 1 | 3 | Rituximab | no | Ocrelizumab | 1 month | March 2020 | Absent, March 2020 | no | April 2020 | POSITIVE | NORMAL | NO | NO | NO | ASYMPTOMATIC | No | IgG- IgM- |
| PATIENT 5 | 36 | RRMS | 11 | 2 | 2 | Rituximab | no | Ocrelizumab | 7 months | September 2019 | Absent, December 2019 | no | April 2020 | UNKNOWN | UNKNOWN | UNKNOWN | UNKNOWN | NO | MILD | No | IgG- IgM- |
| PATIENT 6 | 60 | PPMS | 16 | 7.5 | 0 | NO | NO | Ocrelizumab | 9 years | November 2019 | UNKNOWN | no | March 2020 | UNKNOWN | UNKNOWN | UNKNOWN | UNKNOWN | NO | MILD | NO | NOT DETERMINED |
| PATIENT 7 | 52 | PPMA | 19 | 7.5 | 1 | Glatiramer Acetate | NO | Ocrelizumab | 16 months | October 2019 | Absent October 2019 | no | May 2020 | POSITIVE | UNKNOWN | NO | UNKNOWN | NO | ASYMPTOMATIC | NO | IgG+ IgM+ |
Abbreviations. CRP, C-reactive protein. EDSS, Expanded Disability Status Scale. LDH, lactate dehydrogenase. MS, multiple sclerosis. PP, progressive. RR, relapsing. RT-PCR, reverse transcription polymerase chain reaction.